CIGLIOLA, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 87
AS - Asia 61
EU - Europa 57
Continente sconosciuto - Info sul continente non disponibili 32
SA - Sud America 6
AF - Africa 1
Totale 244
Nazione #
US - Stati Uniti d'America 80
RU - Federazione Russa 46
CN - Cina 27
SG - Singapore 18
IT - Italia 6
VN - Vietnam 5
BD - Bangladesh 4
BR - Brasile 4
CA - Canada 4
JP - Giappone 3
ES - Italia 2
HK - Hong Kong 2
AR - Argentina 1
CO - Colombia 1
DE - Germania 1
FR - Francia 1
GB - Regno Unito 1
GT - Guatemala 1
IN - India 1
IQ - Iraq 1
MX - Messico 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 212
Città #
San Jose 19
Council Bluffs 16
Beijing 10
Singapore 10
Moscow 6
Santa Clara 4
Los Angeles 3
Bologna 2
Brooklyn 2
Ho Chi Minh City 2
Hong Kong 2
Allentown 1
Arapongas 1
Ashburn 1
Aurora 1
Baltimore 1
Brampton 1
Cataguases 1
Charlotte 1
Columbus 1
Corona 1
Da Nang 1
Dakar 1
Dallas 1
Denver 1
Erbil 1
Florence 1
Grand Junction 1
Guatemala City 1
Guelph 1
Hillsborough 1
Jacksonville 1
Lansdowne 1
Loganville 1
London 1
Medellín 1
Mexico City 1
Milwaukee 1
Navsari 1
New York 1
North Kansas City 1
Oldenburg 1
Orem 1
Phú Thọ 1
Phủ Lý 1
Pomona 1
Port of Spain 1
Queen Creek 1
Richmond 1
Rockford 1
Saint-Lazare 1
Salsipuedes 1
San José de la Rinconada 1
Sesto San Giovanni 1
Shanghai 1
São Paulo 1
Tokyo 1
Toronto 1
Westminster 1
Totale 124
Nome #
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 70
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer 42
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) 27
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) 18
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials 14
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) 10
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel 9
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer 8
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study 8
Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report 8
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 7
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 6
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 6
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study 6
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer 5
Totale 244
Categoria #
all - tutte 1.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.208


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/2026174 0 0 0 0 17 9 4 13 52 34 27 18
2026/202770 33 37 0 0 0 0 0 0 0 0 0 0
Totale 244